Choi Jung-Hyun, Song Min-Jin, Kim Seung-Han, Choi Su-Mi, Lee Dong-Gun, Yoo Jin-Hong, Shin Wan-Shik
Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, Korea.
Antimicrob Agents Chemother. 2003 Dec;47(12):3704-7. doi: 10.1128/AAC.47.12.3704-3707.2003.
The effects of moxifloxacin, a new methoxyfluoroquinolone, on the production of proinflammatory cytokines from human peripheral blood mononuclear cells (PBMCs) were evaluated. Moxifloxacin inhibited the production of tumor necrosis factor alpha (TNF-alpha) and/or interleukin-6 (IL-6) by PBMCs stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat-killed bacteria in a concentration-dependent manner without cytotoxic effects. The addition of moxifloxacin reduced the population of cells positive for CD-14 and TNF-alpha and for CD-14 and IL-6 among the LPS- or LTA-stimulated PBMCs. By Western blot analysis, moxifloxacin pretreatment reduced the degradation of IkappaBalpha in LPS-stimulated PBMCs. In conclusion, moxifloxacin could interfere with NF-kappaB activation by inhibiting the degradation of IkappaBalpha and reduce the levels of production of proinflammatory cytokines.
评估了新型甲氧基氟喹诺酮莫西沙星对人外周血单个核细胞(PBMC)促炎细胞因子产生的影响。莫西沙星以浓度依赖的方式抑制脂多糖(LPS)、脂磷壁酸(LTA)和热灭活细菌刺激的PBMC产生肿瘤坏死因子α(TNF-α)和/或白细胞介素-6(IL-6),且无细胞毒性作用。添加莫西沙星可减少LPS或LTA刺激的PBMC中CD-14和TNF-α双阳性以及CD-14和IL-6双阳性细胞的数量。通过蛋白质免疫印迹分析,莫西沙星预处理可减少LPS刺激的PBMC中IkappaBalpha的降解。总之,莫西沙星可通过抑制IkappaBalpha的降解干扰核因子κB(NF-κB)的激活,并降低促炎细胞因子的产生水平。